BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 14, 2012--
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) announced today the launch of an innovative age-based test
protocol that aids physicians when ordering cervical cancer and sexually
transmitted disease (STD) screening tests.
Through this age-based approach, clinicians can select a test number
that will individualize cervical cancer and STD testing based on patient
age (from 21-64) and the corresponding age-based test protocol – as set
forth in the American Congress of Obstetricians and Gynecologists (ACOG)
guidelines.
“This is a novel approach,” said Dr. Mark Brecher, LabCorp’s Chief
Medical Officer. “Offering cervical cancer testing and STD alternatives
that follow the ACOG guidelines for age-based testing provides our
clients an important tool to assist in providing the best possible
patient care.”
This enhancement to LabCorp’s test menu is an adjunct to its broad
women’s health test options, including tests that focus on both
screening and diagnosis of disease. In addition to its women’s health
services, LabCorp offers a comprehensive menu of individual tests and
test combinations to address specific patient needs.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is a pioneer in commercializing new diagnostic technologies and
the first in its industry to embrace genomic testing. With annual
revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and
more than 220,000 clients, LabCorp offers more than 4,000 tests ranging
from routine blood analyses to reproductive genetics to companion
diagnostics. LabCorp furthers its scientific expertise and innovative
clinical testing technology through its LabCorp Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems,
Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine
Sciences. LabCorp conducts clinical trials testing through its LabCorp
Clinical Trials division. LabCorp clients include physicians, government
agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our organization, visit
our Web site at: www.labcorp.com.
This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive actions in
the marketplace and adverse actions of governmental and other
third-party payors. Actual results could differ materially from
those suggested by these forward-looking statements. Further information
on potential factors that could affect LabCorp’s financial results is
included in the Company’s Form 10-K for the year ended December 31,
2011, and subsequent SEC filings.
Source: Laboratory Corporation of America® Holdings
Laboratory Corporation of America® Holdings
Stephen
Anderson, 336-436-5274
www.labcorp.com
